Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells

ABSTRACT: Raw files for the shotgun and targeted carfilzomib protein adduction datasets are included here.

INSTRUMENT(S): Q Exactive Plus, Q Exactive

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Daniel C. Liebler

PROVIDER: MSV000079427 | MassIVE | Fri Dec 18 11:40:00 GMT 2015

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells.

Project description: Not available

| S-EPMC5054346 | biostudies-literature

Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors.

Project description: Not available

| S-EPMC11177207 | biostudies-literature

Covalent modification of primers improves PCR amplification specificity and yield.

Project description: Not available

| S-EPMC6994073 | biostudies-literature

Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.

Project description: Not available

| S-EPMC4467547 | biostudies-literature

Shotgun proteomics experiments to identify covalent modification of proteins in HCT116 cells by a novel covalent ligand, CL16

Project description:By coupling activity-based protein profiling (ABPP) with covalent ligand screening experiment, we have identified a cysteine-reactive covalent ligand, CL16, which can bind strongly and selectively with RhoA in vitro. In this experiment, we performed shotgun proteomics to investigate protein targets of CL16 in colorectal cancer HCT116 cells.

2025-08-30 | PXD053036 | Pride

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma

Project description:Proteasome inhibitor (PI) resistance remains a central challenge in multiple myeloma. To identify pathways mediating resistance, we first map proteasome-associated genetic co-dependencies. We identify cytosolic heat shock protein 70 (HSP70) chaperones as a potential target, consistent with proposed mechanisms of myeloma tumor cells overcoming PI-induced stress. These results led us to explore allosteric HSP70 inhibitors as myeloma therapeutics. We show these compounds exhibit increased efficacy against both acquired and intrinsic PI-resistant myeloma models, unlike HSP90 inhibition. Surprisingly, shotgun and pulsed-SILAC proteomics reveal that JG’s overcome PI resistance not via the expected mechanism of inhibiting cytosolic HSP70s, but instead through mitochondrial-localized HSP70, HSPA9, destabilizing the 55S mitoribosome. Analysis of myeloma patient data further supports strong effects of global proteostasis capacity, and particularly HSPA9 expression, on PI response. Our results characterize dynamics of myeloma proteostasis networks under therapeutic pressure while further motivating investigation of HSPA9 as a specific target in PI-resistant disease.

2020-04-15 | GSE148659 | GEO

Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells.

Project description: Not available

| S-EPMC5412315 | biostudies-literature

Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.

Project description: Not available

| S-EPMC5652320 | biostudies-literature

Template-assisted covalent modification underlies activity of covalent molecular glues.

Project description: Not available

| S-EPMC11582070 | biostudies-literature

BaxΔ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death.

Project description: Not available